RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.

Cell Rep

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Medical College of Wisconsin Cancer Center, Milwaukee, WI 53226, USA. Electronic address:

Published: November 2021

AI Article Synopsis

  • The FXR1 gene is amplified in ovarian cancer patients, leading to increased levels of FXR1 mRNA and protein, which correlate with cancer cell survival and growth.
  • FXR1 enhances overall protein translation in cancer cells by binding to cMYC's AU-rich elements, stabilizing its expression.
  • FXR1 interacts with translation initiation factors, facilitating the circularization of cMYC mRNA and promoting its translation, thereby increasing cMYC levels in cancer cells.

Article Abstract

Fragile X-related protein-1 (FXR1) gene is highly amplified in patients with ovarian cancer, and this amplification is associated with increased expression of both FXR1 mRNA and protein. FXR1 expression directly associates with the survival and proliferation of cancer cells. Surface sensing of translation (SUnSET) assay demonstrates that FXR1 enhances the overall translation in cancer cells. Reverse-phase protein array (RPPA) reveals that cMYC is the key target of FXR1. Mechanistically, FXR1 binds to the AU-rich elements (ARE) present within the 3' untranslated region (3'UTR) of cMYC and stabilizes its expression. In addition, the RGG domain in FXR1 interacts with eIF4A1 and eIF4E proteins. These two interactions of FXR1 result in the circularization of cMYC mRNA and facilitate the recruitment of eukaryotic translation initiation factors to the translation start site. In brief, we uncover a mechanism by which FXR1 promotes cMYC levels in cancer cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675433PMC
http://dx.doi.org/10.1016/j.celrep.2021.109934DOI Listing

Publication Analysis

Top Keywords

cancer cells
12
fxr1
10
protein fxr1
8
translation start
8
start site
8
translation
6
cmyc
5
rna-binding protein
4
fxr1 drives
4
drives cmyc
4

Similar Publications

Probable IgG4-related Orbital Disease Masked by Exuberant Ocular Surface Pseudoepitheliomatous Hyperplasia.

Ophthalmic Plast Reconstr Surg

October 2024

The Operation Eyesight Universal Institute for Eye Cancer, Ophthalmic Pathology Laboratory, LV Prasad Eye Institute, Hyderabad, India.

A 40-year-old woman presented with a mass in her OS for 2 years. Examination revealed a large conjunctival lesion on the nasal bulbar conjunctiva OS and a small upper tarsal conjunctival lesion in the OD. Biopsy OD revealed inflammatory granulation tissue, and OS revealed pseudoepitheliomatous hyperplasia with granulation tissue.

View Article and Find Full Text PDF

STUDY OF CHROMOSOME STABILITY OF HUMAN SOMATIC CELLS IN THE DEVELOPMENT OF THE SECONDARY RADIATION-INDUCED BYSTANDER EFFECT.

Probl Radiac Med Radiobiol

December 2024

State Institution «National Research Center of Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka Str., Kyiv, 04050, Ukraine.

Objective: To establish the level of chromosomal instability in human peripheral blood lymphocytes during thedevelopment of secondary radiation-induced bystander effect.

Materials And Methods: Human peripheral blood lymphocytes; culture of human non-small-cell lung cancer cell lineA549 (irradiated in vitro by 137Cs in a dose of 0.50 Gy/unirradiated).

View Article and Find Full Text PDF

This study aims to demonstrate the effect of toadflax (bufalin) on erlotinib resistance in nonsmall cell lung cancer (NSCLC) by inhibiting the fibroblast growth factor receptor (FGFR). The microfluidic mobility transferase and caliper mobility-shift assays were employed to detect the FGFR inhibition by bufalin and the binding reversibility. Further, the inhibitory effects of bufalin were determined in HCC827 and HCC827/ER cells in vitro, investigating relative FGFR overexpression by quantitative reverse transcriptase-PCR (RT-qPCR) and FGFR downstream proteins, that is, FGFR substrate 2 (FRS2), extracellular signal-regulated kinase (ERK), and S6 by western blot analysis.

View Article and Find Full Text PDF

Study Question: How can we best achieve tissue segmentation and cell counting of multichannel-stained endometriosis sections to understand tissue composition?

Summary Answer: A combination of a machine learning-based tissue analysis software for tissue segmentation and a deep learning-based algorithm for segmentation-independent cell identification shows strong performance on the automated histological analysis of endometriosis sections.

What Is Known Already: Endometriosis is characterized by the complex interplay of various cell types and exhibits great variation between patients and endometriosis subtypes.

Study Design, Size, Duration: Endometriosis tissue samples of eight patients of different subtypes were obtained during surgery.

View Article and Find Full Text PDF

Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments.

FASEB J

December 2024

Antibody and Vaccine Group, Faculty of Medicine, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Southampton, UK.

Osteosarcoma is the most common primary bone cancer, occurring frequently in children and young adults. Patients are treated with surgery and multi-agent chemotherapy, and despite the introduction of mifamurtide in 2011, there has been little improvement in survival for decades. 3-dimensional models offer the potential to understand the complexity of the osteosarcoma tumor microenvironment and aid in developing new treatment approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!